Showing 1131-1140 of 1576 results for "".
- Dell, HP, Lenovo and Acer to Announce New Eyesafe Products at the Blue Light Summit 2020https://modernod.com/news/dell-hp-lenovo-and-acer-to-announce-new-eyesafe-products-at-the-blue-light-summit-2020/2478378/Eyesafe, UnitedHealthcare Vision, and TÜV Rheinland Group announced the dates and registration details as well as the initial lineup of companies and thought leaders participating in the Blue Light Summit 2020. This year’s event will be held on Oct. 15, 2020. D
- Samsung Bioepis and Biogen Announce EMA Filing Acceptance of Proposed Lucentis Biosimilarhttps://modernod.com/news/samsung-bioepis-and-biogen-announce-ema-filing-acceptance-of-proposed-lucentis-biosimilar/2478376/Samsung Bioepis and Biogen announced that the European Medicines Agency (EMA) has accepted for review its Marketing Authorization Application for SB11, a proposed biosimilar referencing Lucentis (ranibizumab). Ranibizumab is an anti-VEGF (vascular endothelial growth factor) for retinal vascular d
- Bausch Health Acquires Option To Purchase Ophthalmology Assets Of Allegro Ophthalmicshttps://modernod.com/news/bausch-health-to-acquire-option-to-purchase-all-ophthalmology-assets-of-allegro-ophthalmics/2478300/Bausch Health has entered into an agreement to acquire an option to purchase all ophthalmology assets of Allegro Ophthalmics, including global rights for risuteganib (Luminate)1, Allegro’s lead investigational compound in retina. Full financial terms of the deal were not d
- Dosing Begins in Phase 1 Study of AstraZeneca’s Antibody Combination for COVID-19https://modernod.com/news/dosing-begins-in-phase-1-study-of-astrazenecas-antibody-combination-for-covid-19/2478204/AstraZeneca announced that the first subjects have been dosed in a phase 1 study of AZD7442, a combination of two monoclonal antibodies under development for the prevention and treatment of COVID-19. Mene Pangalos, executive vice president of biopharmaceuticals R&D, said “this combinati
- US Secures At Least 100 Million Doses of Moderna’s COVID-19 Vaccine for $1.5 Billionhttps://modernod.com/news/us-secures-at-least-100-million-doses-of-modernas-covid-19-vaccine-for-1-5-billion/2478151/Moderna on Tuesday said it reached an agreement with the US government to supply millions of doses of its coronavirus vaccine candidate mRNA-1273. The award of up to $1.525 billion is for the manufacturing and delivery of 100 million doses of the vaccine, including incentive payments for timely d
- Inovio Hints at Positive Early Phase 1 Safety Data for COVID-19 Vaccine INO-4800https://modernod.com/news/inovio-hints-at-positive-early-phase-1-safety-data-for-covid-19-vaccine-ino-4800/2477810/Inovio Pharmaceuticals suggested that preliminary safety data from an ongoing phase 1 trial indicates that its experimental COVID-19 DNA vaccine candidate INO-4800 appears to be safe in humans. “We are already seeing safety data and it has been benign,” commented R&D head K
- BVI Expands Portfolio with New Viscoelastic; Forges Strategic Partnership with Cromahttps://modernod.com/news/bvi-expands-portfolio-with-new-viscoelastic-forges-strategic-partnership-with-croma/2477789/BVI announced it has acquired the ophthalmic viscoelastic device (OVD) assets from Austrian-based Croma. In addition to the acquisition of existing products, BVI and Croma have embarked on an R&D collaboration on additional products that will come to market. Terms of the deal were not
- Visibly Offers Free Telehealth Vision Tests During COVID-19 Pandemichttps://modernod.com/news/visibly-offers-free-telehealth-vision-tests-during-covid-19-pandemic/2477627/Visibly announced that it will globally provide optometrists, ophthalmologists, and optical service providers free access to its virtual vision test technology to ensure that patients can meet their eye health needs during this unprecedented time. “We are thrilled to offer Visibly to all d
- ProtoKinetix AAGP Exhibits Efficacy and Safety in Model of Dry Eye Diseasehttps://modernod.com/news/protokinetix-aagp-exhibits-efficacy-and-safety-in-model-of-dry-eye-disease/2479530/ProtoKinetix, which recently announced filing for patent protection for new applications of its AAGP (PKX-001) molecule, announced preliminary results in efficacy and safety for use in treating dry eye disease (DED). PKX-001 demonstrated a protective effect in the murine model of dry eye d
- ARVO Annual Meeting Cancelledhttps://modernod.com/news/arvo-annual-meeting-cancelled/2477380/Due to the COVID-19 outbreak, the Board of Trustees at The Association for Research in Vision and Ophthalmology (ARVO) has decided to cancel its annual meeting, scheduled to take place May 1–7 in Baltimore. The ARVO organizers released an emailed statement to its membership outlining the d